Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 30 million for breast cancer trial

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 19, 2024 7:33pm

98 Views

Post# 36232156

RE:30 million for breast cancer trial

ONCY has $500 million in R&D write-offs and the potential of $US 5.89 Billion in peak annual sales for the 3rd line HR+/HER2- breast cancer alone, and with 13 years of FDA market exclusivity from the approval date of pelareorep.

And then there are the PDAC, anal cancer, TNBC and GI cancer indications as follow-on approvals.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant